Christopher J. Lord - Concepedia

Author

Christopher J. Lord

Institute of Cancer Research ORCID

Also Known As

Alan Lipps, Brian McDade, C J Lord, C. J. Lord, C. Lord, C.J. LORD, C.J. Lord, CJ Lord, Chris J Lord, Chris J. Lord

702

Publications

44.8K

Citations

H-Index

121

Concepts

All Affiliations

Institute of Cancer Research Breast Cancer Now Cancer Research UK Royal Marsden NHS Foundation Trust Breast Cancer Research Foundation

About

Christopher J. Lord is an author at Institute of Cancer Research specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	52	72	16.6K
2	Natural Sciences	15	16	2K
3	Engineering	8	8	886
4	Health Sciences	4	4	471
5	Public Health	3	3	117

Christopher J. Lord

174

Publications

31.3K

Citations

H-Index

Page 1

	Year	Citations
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Hannah Farmer, Nuala McCabe, Christopher J. Lord, Nature Genome InstabilityDna DamageBrca Mutant CellsMedicineMolecular Biology	2005	6.5K
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu, New England Journal of Medicine	2015	2.1K
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition Nuala McCabe, Nicholas C. Turner, Christopher J. Lord, Cancer Research	2006	1.3K
Resistance to therapy caused by intragenic deletion in BRCA2 Stacey L. Edwards, Rachel Brough, Christopher J. Lord, Nature Intragenic DeletionOncogenic AgentPathologyCancer GeneticsMedicine	2008	979
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer María Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, Cancer Research Pi3k InhibitorsBreast OncologyEstrogen ReceptorCancer BiologyTumor Biology	2016	742
The shieldin complex mediates 53BP1-dependent DNA repair Sylvie M. Noordermeer, Salomé Adam, Dheva Setiaputra, Nature ChromatinGenome InstabilityChromatin RemodelingMolecular Biology53Bp1-dependent Dna Repair	2018	635
Synthetic lethal targeting of <i>PTEN</i> mutant cells with PARP inhibitors Ana M. Mendes‐Pereira, Sarah A. Martin, Rachel Brough, EMBO Molecular Medicine Drug TargetingSynthetic Lethal TargetingMolecular BiologyCell DeathAnti-cancer Agent	2009	618
Germline mutations in RAD51D confer susceptibility to ovarian cancer Chey Loveday, Clare Turnbull, Emma Ramsay, Nature Genetics GeneticsGermline MutationsCancer GeneticsMedicineOvarian Cancer	2011	526
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency Yuqiao Shen, Farah Rehman, Ying Feng, Clinical Cancer Research	2013	477
Genetic Interactions in Cancer Progression and Treatment Alan Ashworth, Christopher J. Lord, Jorge S. Reis‐Filho Cell Tumor BiologyOncologyMedicineCancer GenomicsGenetic Interactions	2011	441

Page 1